Phase 4
Completed N=22
Comparison of Blood Pressure Medications on Metabolism
Source: ClinicalTrials.gov NCT00642434 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcomePrimary: Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline — 0; 0 participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to determine if there are differences, (benefits) between carvedilol and metoprolol in the treatment of HTN in patients with type 2 diabetes. Specifically we will be looking at differences in blood pressure and blood sugar control, endothelial function, inflammation, oxidative stress and coagulation.
Subjects will be randomized to one of the two beta-blockers and followed for 5 months. Each subject will undergo 4 inpatient studies where an oral glucose tolerance test will be done, Inflammatory and oxidative stress markers will be measured. Endothelial function will be measured using brachial artery ultrasound and laser skin Doppler
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- not enrolling
Exclusion Criteria
- not enrolling
Data sourced from ClinicalTrials.gov (NCT00642434). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.